NEW YORK (GenomeWeb) – Intellimedix said today that it is collaborating with BGI Tech to offer an exome sequencing service on Thermo Fisher's Ion Proton at 100x coverage.
The service will use Intellimedix's interpretative software, Prognostix, developed by Jeffrey Skolnick, director of the Center for the Study of Systems Biology at the Georgia Institute of Technology and a scientific advisor to Intellimedix.
Prognostix incorporates 3D protein structure to make more precise predictions about a DNA mutation's possible pathogenicity. According to Intellimedix, it has a three-fold lower rate of false positives.
The service will have a 10-day turnaround time — seven for sequencing and three for full interpretation and annotation — as opposed to the industry norm of eight weeks, according to Intellimedix.
"Our joint effort will redefine customer service in the exome research marketplace, setting a new standard across the genomic sequencing and interpretation industry," Skolnick said in a statement.
"Coupling our exome service with Intellimedix's proprietary algorithms will provide researchers rapid, in-depth sequencing with enhanced annotation and interpretation," BGI CEO Yingrui Li said in the statement.